Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)

被引：10

作者：

Perrot, Aurore ^{[1
]}

Lauwers-Cances, Valerie ^{[2
]}

Touzeau, Cyrille ^{[3
]}

Decaux, Olivier ^{[4
]}

Hulin, Cyrille ^{[5
]}

Macro, Magaret ^{[6
]}

Stoppa, Anne-Marie ^{[7
]}

Chretien, Marie Lorraine ^{[8
]}

Karlin, Lionel ^{[9
]}

Mariette, Clara ^{[10
]}

Jacquet, Caroline ^{[11
]}

Roussel, Murielle ^{[12
]}

Guillemot, Coralie ^{[13
]}

Devlamynck, Laure ^{[2
]}

Avet-Loiseau, Herve ^{[14
]}

Moreau, Philippe ^{[15
]}

Attal, Michel ^{[16
]}

机构：

[1] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[2] CHU Toulouse, serv Epidemiol, USMR, Toulouse, France

[3] CHU Nantes, Hematol, Ctr Rech Cancerol & Immunol Nantes Angers CRCINA, Nantes, France

[4] CHU Rennes, Serv Hematol, Rennes, France

[5] Hop Haut Leveque, Univ Hosp, Pessac, France

[6] Ctr Hosp Univ CHU Caen, Caen, France

[7] Inst Paoli Calmettes, Marseille, France

[8] CHU Dijon, Serv Hematol Clin, Dijon, France

[9] Univ Claude Bernard Lyon 1, CHU Lyon Sud, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[10] CHU Grenoble, Serv Hematol, Grenoble, France

[11] CHRU Nancy, Vandoeuvre Les Nancy, France

[12] CHU Limoges, Hematol, Limoges, France

[13] IUCT Oncopole, Pharm Unite Essais Clin, Toulouse, France

[14] UPS, CHU Toulouse, Unite Genom Myelome, IUCT Oncopole, Toulouse, France

[15] CHU Nantes, Nantes, France

[16] Inst Univ Canc Toulouse Oncopole, Toulouse, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-146040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

464

引用

页数：5

共 50 条

[21] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
O'Donnell, Elizabeth K.
Suman, Vera Jean
Geyer, Susan M.
Nadeem, Omar
Dinner, Shira
Yee, Andrew J.
Laubach, Jacob P.
Mo, Clifton C.
Tuchman, Sascha A.
Donadio, Kristen
Sinclair, Sarah
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138
[22] Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Dimopoulos, Meletios
Boccadoro, Mario
Hang Quach
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels
Liu, Yanfang
Wang, Jianping
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Rodriguez-Otero, Paula
Blade, Joan
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S246 - S246
[23] Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.
Ishida, Tadao
Kimura, Hideo
Kubo, Koumei
Sunami, Kazutaka
Ozaki, Shuji
Takezako, Naoki
Handa, Hiroshi
Kosugi, Hiroshi
Murakami, Hirokazu
Shimizu, Kazuyuki
BLOOD, 2015, 126 (23)
[24] An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne A.
Reeves, Brandi
Wildes, Tanya M.
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf Z.
Shune, Leyla O.
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 10154 - 10156
[25] Phase 3 randomized study of Daratumumab plus lenalidomide and Dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)
Weisel, K.
Facon, T.
Kumar, S.
Plesner, T.
Orlowski, R. Z.
Moreau, P.
Bahlis, N.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Mace, J. R.
Ahmadi, T.
Chiu, C.
Wang, J.
van Rampelbergh, R.
Uhlar, C. M.
Kobos, R.
Qi, M.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 194 - 194
[26] Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Ahmadi, Tahamtan
Chiu, Christopher
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Qi, Ming
Usmani, Saad Z.
BLOOD, 2018, 132
[27] A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)
Berdeja, Jesus G.
Gregory, Tara K.
Kambhampati, Suman
Anz, Bertrand M., III
Tarantolo, Stefano R.
Meluch, Anthony A.
Matous, Jeffrey V.
BLOOD, 2019, 134
[28] Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph, Nisha S.
Kaufman, Jonathan L.
Dicamillo, Sara
Roberts, Danielle
Gupta, Vikas A.
Hofmeister, Craig C.
Dhodapkar, Madhav V.
Boise, Lawrence H.
Lonial, Sagar
Nooka, Ajay K.
BLOOD, 2023, 142
[29] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Moreau, Philippe
Dimopoulos, Meletios A.
Quach, Hang
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels W. C. J.
Katodritou, Eirini
Schjesvold, Fredrik
Sureda Balari, Anna
Rosinol, Laura
Delforge, Michel
Roeloffzen, Wilfried
Driessen, Christoph
Vangsted, Annette
Einsele, Hermann
Spencer, Andrew
Hajek, Roman
Jurczyszyn, Artur
Lonergan, Sarah
Liu, Yanfang
Wang, Jianping
Vieyra, Diego
van Brummelen, Emilie M. J.
Vanquickelberghe, Veronique
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Boccadoro, Mario
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S550 - S551
[30] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
Chari, Ajai
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Usmani, Saad
Voorhees, Peter M.
BLOOD, 2022, 140 : 7278 - 7281

← 1 2 3 4 5 →